Discussing the Future of Treatment in Oligometastatic Prostate Cancer


Chad Tang discusses where he sees the future of treatment for patients with oligometastatic prostate cancer heading and how the phase 2 EXTEND trial will impact this patient population.

Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discusses where he sees the future of the treatment landscape for patients with oligometastatic prostate cancer heading.

In an interview with Targeted OncologyTM, Tang discussed the findings of the phase 2 EXTEND trial (NCT03599765) that showed an improvement in progression-free survival for patients with oligometastatic prostate cancer given a combination of metastasis-directed therapy and intermittent hormone therapy.

Tang explained that the basket study showed that between patients given hormone therapy with (n = 43) or without (n = 44) local therapy those given the combination therapy had a longer median PFS at 15.8 months vs not reached for those patients given hormone therapy alone (HR, 0.25; 95% CI, 0.12-0.55, P < .001). Moreover, patients who eventually hit their normal level of testosterone also saw improved PFS.

Tang discusses how this study could impact the future of treatment for this patient population. Moreover, he looks at how the future of treatment of these patients is going towards preventing adverse events while maintaining efficacy results.  


0:08 | There may be some interest in the future potentially utilizing, not only metastasis-directed therapy, but also an intermittent hormone therapy regime, as these men can often be years without hormone therapy. It can convert universally lethal disease when you compare these 2 modalities in select patients with chronic disease.

0:30 | Not only that, but there are substantial amounts of time with a chronic disease when you get to recover your testosterone and all men benefit from that because. Not only does it prevent all these adverse events, such as hot flashes, night sweats, loss of libido, it also causes increased incidence of cardiovascular risk of stroke, obese, adiposity, etc. I think it's a big win for patients if we can develop these chronic strategies that not only treat the disease with extra control, but also maintain a quality of life.

Related Videos
Video 8 - "Clinical Pearls for Optimal Management of mHSPC"
Video 7 - "Multidisciplinary Approach in mHSPC Management "
Video 6 - "Treatment Considerations in High Disease Burden and Comorbidities"
Video 5 - "Pivotal Trials in mHSPC"
Video 4 - "ARASENS Trial- Darolutamide in mHSPC"
Video 3 - "Treatment Intensification in Metastatic Prostate Cancer"
Video 2 - "Treatment Options for mHSPC"
Video 1 - "Initial Impression and Risk Assessment"
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Related Content